Tranilast Prevents Atrial Remodeling and Development of Atrial Fibrillation in a Canine Model of Atrial Tachycardia and Left Ventricular Dysfunction  by Nakatani, Yosuke et al.
Journal of the American College of Cardiology Vol. 61, No. 5, 2013
© 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00PRE-CLINICAL RESEARCH
Tranilast Prevents Atrial Remodeling and
Development of Atrial Fibrillation in a Canine Model
of Atrial Tachycardia and Left Ventricular Dysfunction
Yosuke Nakatani, MD,* Kunihiro Nishida, MD, PHD,* Masao Sakabe, MD, PHD,†
Naoya Kataoka, MD,* Tamotsu Sakamoto, MD, PHD,* Yoshiaki Yamaguchi, MD,*
Jotaro Iwamoto, MD,* Koichi Mizumaki, MD, PHD,* Akira Fujiki, MD, PHD,†
Hiroshi Inoue, MD, PHD*
Toyama and Shizuoka, Japan
Objectives This study sought to assess the effects of tranilast on atrial remodeling in a canine atrial fibrillation (AF) model.
Background Tranilast inhibits transforming growth factor (TGF)-1 and prevents fibrosis in many pathophysiological settings.
However, the effects of tranilast on atrial remodeling remain unclear.
Methods Beagles were subjected to atrial tachypacing (400 beats/min) for 4 weeks while treated with placebo (control
dogs, n  8) or tranilast (tranilast dogs, n  10). Sham dogs (n  6) did not receive atrial tachypacing. Atrioven-
tricular conduction was preserved. Ventricular dysfunction developed in the control and tranilast dogs due to
rapid ventricular responses.
Results Atrial fibrillation duration (211  57 s) increased, and AF cycle length and atrial effective refractory period short-
ened in controls, but these changes were suppressed in tranilast dogs (AF duration, 18  10 s, p  0.01 vs.
control). The L-type calcium channel 1c (Cav1.2) micro ribonucleic acid expression decreased in control dogs
(sham 1.38  0.24 vs. control 0.65  0.12, p  0.01), but not in tranilast dogs (0.97  0.14, p  not signifi-
cant vs. sham). Prominent atrial fibrosis (fibrous tissue area, sham 0.8  0.1 vs. control 9.3  1.3%, p  0.01)
and increased expression of tissue inhibitor of metalloproteinase protein 1 were observed in control dogs but not
in tranilast dogs (fibrous tissue area, 1.4  0.2%, p  0.01 vs. control). The TGF-1 (sham 1.00  0.07 vs. con-
trol 3.06  0.87, p  0.05) and Rac1 proteins were overexpressed in control dogs, but their overexpression was
inhibited in tranilast dogs (TGF-1, 1.28  0.20, p  0.05 vs. control).
Conclusions Tranilast prevented atrial remodeling and suppressed AF development in a canine model. Its inhibition of TGF-1
and Rac1 overexpression may contribute to its antiremodeling effects. (J Am Coll Cardiol 2013;61:582–8)
© 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.014Atrial fibrillation (AF), the most common sustained tachyar-
rhythmia in clinical practice (1), is associated with serious
potential complications and mortality (2). Atrial fibrillation
and concurrent cardiac disorders cause atrial structural and
electrical remodeling and further AF development (3). Atrial
fibrosis is a main contributor to the AF substrate, which occurs
in various pathological settings such as senescence, heart
failure, and myocardial ischemia, resulting in conduction het-
erogeneity, which facilitates re-entry and AF occurrence (4,5).
From the *Second Department of Internal Medicine, University of Toyama, Toyama,
Japan; and the †Division of Cardiology, Shizuoka Red Cross Hospital, Shizuoka,
Japan. The authors have reported they have no relationships relevant to the contents
of this paper to disclose.Manuscript received August 17, 2012; revised manuscript received October 26,
2012, accepted November 5, 2012.Another important factor underlying AF is rate-related elec-
trical remodeling (6). A rapid atrial rate causes heterogeneous
shortening of the atrial effective refractory period (AERP) and
increases the inducibility and persistence of AF (7,8).
Tranilast, N-(3,4-dimethoxycinnamoyl) anthranilic acid,
is an antiallergic drug with multiple effects, including
inhibition of extracellular matrix protein synthesis, cell
proliferation, and inflammatory response (9). Tranilast is
clinically used for treatment of hypertrophic scar and keloid
formation (10). Tranilast prevents ventricular fibrosis in
hypertensive (11) and diabetic (12) cardiomyopathy, but the
atrial effect has not been clarified. Although the atrium and
ventricle exhibit different fibrotic responses (13,14), tranilast
may prevent atrial fibrosis and AF development.
We examined the effect of tranilast on atrial remodeling
and AF development using a canine atrial tachypacing
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February 5, 2013:582–8 Tranilast and Atrial Fibrillationmodel with preserved atrioventricular conduction, which
develops concomitant tachycardia-induced ventricular dys-
function (15). In this model, both atrial electrical and
structural remodeling are observed (16,17).
Methods
For details, see supplementary material in the Online Appendix.
Experimental design. The investigation conformed to the
Guide for the Care and Use of Laboratory Animals published
by the U.S. National Institutes of Health (NIH publication
No. 85-23, revised 1996). The procedures were approved by
the Animal Research Ethics Committee of the University of
Toyama. Twenty-four beagles were divided into control
(n  8), tranilast (n  10), and sham (n  6) groups. Dogs
n the control and tranilast groups were subjected to atrial
achypacing of 400 beats/min for 4 weeks. These groups
eceived oral placebo and tranilast (50 mg/kg/day), respec-
ively, during the study protocol.
nimal preparation. All dogs were implanted with an
trial tachypacemaker, as previously described (16–18). A
etrapolar electrode was sewn onto the right atrium (RA)
picardium for stimulation and recording during serial
lectrophysiological study. Atrioventricular ablation was not
erformed. After a 7-day recovery period, the atrial tachypace-
akers in control and tranilast dogs were programmed to pace
he atria at a cycle length of 150 ms (400 beats/min). Atrial
achypacemakers in sham dogs were not activated.
lectrophysiological study. An electrophysiological study
as performed every week in tranilast and control dogs.
trial tachypacemakers were deactivated before every elec-
rophysiological study. Stimulation and recording were per-
ormed using the implanted RA electrode. A transesopha-
eal electrode lead was inserted to record a left atrium (LA)
lectrogram. The atrial effective refractory period (AERPs)
ere measured with a train of 10 basic stimuli (S1) followed
y a premature stimulus (S2). Induction of AF was at-
empted through atrial burst pacing of 20 stimuli at the
inimum cycle length producing 1:1 atrial capture. Induc-
bility of AF was defined as the number of induced AF
pisodes of 10 such attempts, expressed as a proportion. The
F duration was represented by the mean and the longest
uration of induced AF episodes in each dog.
The AF cycle length (AFCL) was determined using fast
ourier transformation of the stored atrial electrograms, as
reviously reported (17,19). Power spectra were quantified
y measuring the peak frequency signal and then converted
o a cycle length (cycle length in ms  1,000/frequency)
abeled AFCL.
chocardiographic measurements. Echocardiographic
easurements were performed every week with the pace-
aker deactivated. By means of transthoracic echocardiog-
aphy, left ventricular end-diastolic and end-systolic dimen-
ions were measured, and left ventricular ejection fraction
alculated. The LA area was measured in the 2-chamber view
y transesophageal echocardiography.istological examination. At
he end of the experiments, all
nimals were euthanized and LA
ree wall tissue obtained. Formalin-
xed paraffin-embedded tissues
ere stained with Masson’s
richrome and connective tissue
reas quantified using a color dis-
rimination algorithm.
uantitative real-time reverse
ranscriptase-polymerase chain
eaction. Samples were ob-
ained from the LA free wall.
nalysis was performed using
aqMan technology. The micro
ibonucleic acid (mRNA) levels
f L-type calcium channel 1c
Cav1.2) and transient outward
otassium channel (Kv4.3) were
uantified (Online Table 1).
estern blot analysis. Protein
xpression levels of transforming
rowth factor-1 (TGF-1),
ac1, RhoA, and tissue inhibitor of metalloproteinase
TIMP) 1 and 4 were quantified through Western blotting.
nzyme-linked immunosorbent assay. Blood samples were
ollected on the final study day, and serum was stored at
80°C for subsequent analyses. C-reactive protein and
nterleukin-6 were measured by enzyme-linked immunosor-
ent assay.
tatistical analysis. All values are expressed as mean 
EM. An unpaired t test and a Mann-Whitney U test were
used to evaluate the significance of differences between the
2 groups. Statistical significance of multiple-group compar-
ison was analyzed using 1-way analysis of variance, and the
time series data using 2-way repeated measures analysis of
variance with time as a repeated factor. If significant effects
were revealed, post-hoc tests with Bonferroni-adjusted pair-
wise comparisons were performed. A p value of 0.05 was
considered statistically significant.
Results
Echocardiographic characteristics. Echocardiography re-
vealed the development of left ventricular dysfunction in
both control and tranilast dogs (Online Fig. 1). Left
ventricular end-diastolic and end-systolic dimensions en-
larged and left ventricular ejection fraction decreased signif-
icantly after 1 week of atrial tachypacing (Online Fig. 1).
The LA area enlarged during atrial tachypacing in both
control and tranilast dogs, becoming significantly larger at 1
to 4 weeks than at baseline (Online Fig. 2). The 2 groups’
echocardiographic indices did not differ at any time point
(Online Figs. 1 and 2).
Electrocardiographic characteristics. No significant time-
Abbreviations
and Acronyms
AERP  atrial effective
refractory period
AF  atrial fibrillation
AFCL  atrial fibrillation
cycle length
BCL  basic cycle length
GAPDH  glyceraldehyde-3-
phosphate dehydrogenase
LA  left atrium
mRNA  micro ribonucleic
acid
NADPH  nicotinamide
adenine dinucleotide
phosphate
RA  right atrium
TGF  transforming growth
factor
TIMP  tissue inhibitor of
metalloproteinasecourse change or between-group difference was observed in
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Tranilast and Atrial Fibrillation February 5, 2013:582–8either ventricular response rate during atrial tachypacing,
sinus rate with pacemaker deactivated, or shortest atrial
pacing cycle length with 1:1 atrioventricular conduction
(Online Table 2). The P-wave duration tended to lengthen
slightly in both groups, but no statistically significant
temporal changes or between-group differences were ob-
served in P-wave duration, QRS duration, or QT interval
during the experiment (Online Fig. 3).
Promotion of AF. Inducibility of AF (Fig. 1A) increased
n both groups, but this increase was suppressed in tranilast
ogs (control 44 9% vs. tranilast 14 5% at 4 weeks, p
.01). The mean (Fig. 1B) and longest (Fig. 1C) AF
urations lengthened through the protocol in control dogs.
n tranilast dogs, in contrast, AF perpetuation was largely
Week
A
(%)
**
**
Week
(s)
B
*
**
Week
C
(s)
**
Mean AF
duraon
Longest AF
duraon
Control group Tranilast group
AF
inducibility
Figure 1 Parameters of AF Promotion
Time-course changes in atrial fibrillation (AF) inducibility (A), mean AF duration
(B), and longest AF duration (C). *p  0.05 and **p  0.01 tranilast group
(blue circles) versus control group (red circles).
RA
LA
Peak fre
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AFCL     
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Peak fre
9.8 Hz
AFCL     
102 ms
RA
LA
B Tra
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10 128 146 (Hz)
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AFCL     
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A Control
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Figure 2 Frequency Characteristics of AF
Representative atrial electrograms and examples of atrial fibrillation (AF) spectral
tranilast dogs was obtained from the tranilast dog with the longest AF episode, in
(AFCL). *p  0.05 and **p  0.01 tranilast group (blue circles) versus control guppressed (at 4 weeks: mean AF, control 37  6 s vs.
ranilast 6  3 s, p  0.01; maximum AF, control 211 
7 s vs. tranilast 18  10 s, p  0.01).
requency characteristics of AF. In a control-group dog,
trial electrograms during AF showed faster activation;
pectral analysis revealed AFCLs of 98 and 89 ms in RA
nd LA, respectively (Fig. 2A). In a tranilast-group dog,
trial activation was slower; spectral analysis revealed
FCLs of 114 ms and 102 ms in RA and LA (Fig. 2B).
he AFCLs gradually shortened in control dogs, but not in
ranilast dogs (Fig. 2C). The AFCLs were longer in tranilast
ogs than in control dogs at 4 weeks (RA, control 95  7 ms
s. tranilast 117  2 ms, p  0.01; LA, control 91 
ms vs. tranilast 105  3 ms, p  0.01).
hanges in AERP. Changes in AERP at a BCL of 200
s are presented in Figure 3A. The AERP shortened
rastically at 1 week and gradually thereafter in control
ogs. In tranilast dogs, AERP also shortened at 1 week
ut the degree of its subsequent shortening was much
maller than in control dogs. The AERP was significantly
onger in tranilast dogs than in control dogs at 4 weeks
control 94  5 ms vs. tranilast 112  3 ms, p  0.01)
Fig. 3A). The AERPs as a function of BCL did not
iffer among the groups at baseline (Fig. 3B) and at 1
eek (Fig. 3C); at 4 weeks, however, they were signifi-
antly longer in tranilast dogs than in control dogs (Fig. 3D).
he time-course changes in AERP were nearly parallel to
he changes in AFCL, suggesting the possible causal
nvolvement of altered atrial electrophysiology in AF
romotion.
trial ion-channel remodeling. The Cav1.2 mRNA sig-
ificantly decreased in control dogs compared with sham
Week
(ms)
Week
(ms)
RA
LA
C AFCL
**
***10 128 14 (Hz)
10 128 14 (Hz)
y
y
st
Control group
Tranilast group
500 ms
es in (A) control dogs and (B) tranilast dogs. The example of spectral analysis in
AF lasted for maximum of 110 s. (C) Time-course changes in AF cycle length
ed circles). LA  left atrium; RA  right atrium.6
6
quenc
quenc
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analys
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roup (r
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February 5, 2013:582–8 Tranilast and Atrial Fibrillationdogs (Fig. 4A), but its down-regulation was prevented in
tranilast dogs, namely, there were no significant reduc-
tions in Cav1.2 mRNA in tranilast versus sham dogs
(Fig. 4A). The KV4.3 mRNA was also significantly
decreased in control dogs compared to sham dogs, but
KV4.3 mRNA down-regulation was not prevented in
tranilast dogs (Fig. 4B).
Atrial structural remodeling. Atrial histology of sham
dogs displayed grossly normal atria with small amounts of
interstitial fibrous tissue (Fig. 5A), in contrast to the
substantial interstitial fibrosis in control dogs (Fig. 5B). In
tranilast dogs, however, interstitial fibrosis was almost
completely suppressed (Figs. 5C and 5D).
Signal transductions involved in atrial remodeling.
Atrial protein expressions are shown in Figure 6. The
TGF-1 increased in control dogs (sham 1.00  0.07 vs.
BCL (ms)
B
(ms)
Week
(ms)
A
* * * *
* * * *
†
AERP
(BCL 200 ms)
AERP
Baseline
Contro
Figure 3 Changes in AERP
(A) Time-course changes in atrial effective refractory period (AERP) determined at
weeks at each BCL. *p  0.01 versus baseline (0 weeks), and †p  0.01 tranila
with vertical bars represent treatment group main effects.
A
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Figure 4 Cav1.2 and KV4.3 mRNA Expression
Atrial micro ribonucleic acid (mRNA) expression of (A) L-type calcium channel 1c
*p  0.05 and **p  0.01 versus sham group.control 3.06  0.87, p  0.05), while that in tranilast dogs
remained at a lower level similar to that in sham dogs
(tranilast 1.28  0.20, p  0.05 vs. control) (Fig. 6A). This
was also true for Rac1 (sham 1.00  0.09; control 1.68 
0.08, p 0.05 vs. sham; tranilast 0.81 0.15, p 0.001 vs.
control) (Fig. 6B). The RhoA expression did not differ
among the 3 groups (Fig. 6C). The TIMP1 increased in
control dogs compared with sham dogs (sham 1.00 0.12 vs.
control 1.74  0.26, p  0.05) (Fig. 6D), while alteration in
TIMP1 protein expression was fully suppressed in tranilast
dogs (0.75  0.07, p  0.05 vs. control) (Fig. 6D). The
TIMP4 expression did not differ among the 3 groups
(Fig. 6E). Serum inflammatory markers, C-reactive protein, and
interleukin-6, tended to increase in control and tranilast dogs
compared with sham dogs; however, the differences between the
groups were not statistically significant (Online Fig. 4).
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Major findings. The major findings of the present study
are: 1) tranilast prevented the development of AF, and
suppressed AERP shortening and Cav1.2 mRNA down-
regulation; and 2) tranilast prevented both atrial interstitial
fibrosis and the increase in TIMP1, TGF-1, and Rac1
protein expressions.
Potential mechanisms underlying the effects of tranilast
on atrial structural remodeling. The present study is the
first to demonstrate the antifibrotic effect of tranilast in
the atrium. Known antifibrotic actions of tranilast include
the inhibition of TGF-1 (20,21), which stimulates the
proliferation of fibroblasts and their phenotypic conversion
to myofibroblasts (14,22). Tissue fibrosis and TGF-1
overexpression are more prominent in the atrium than in the
ventricle in a canine model of congestive heart failure (13),
and the antifibrotic drug pirfenidone has prevented
TGF-1 overexpression together with atrial fibrosis and AF
promotion in the same model (23). In the present study,
tranilast prevented overexpression of TGF-1 in a canine
AF model induced by atrial tachypacing with preserved
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Figure 5 Histological Analysis of Atrial Fibrosis
Masson’s trichrome-stained light micrographs (original magnification 400) in
representative (A) sham, (B) control, and (C) tranilast dogs. (D) The propor-
tion of area of interstitial fibrous tissue is shown among the 3 groups. Scale
bar  100 m. *p  0.01 versus sham group, and †p  0.01 versus control
group.GAPDH
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Figure 6 Western Blotting Analyses
Atrial expression of (A) transforming growth factor (TGF)-1, (B) Rac1, (C) RhoA, (D) tis
are shown at the top of each panel, along with corresponding glyceraldehyde-3-phosphat
0.05 and ††p  0.001 versus control group. ATP  atrial tachypacing.
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February 5, 2013:582–8 Tranilast and Atrial Fibrillationatrioventricular conduction, suggesting that its antiremod-
eling effects are, at least partly, due to TGF-1 inhibition.
The TIMPs regulate the extracellular matrix deposition
hrough inhibition of matrix metalloproteinases (23–25).
ncreased TIMP1 in atrial tachypacing dogs in the present
tudy was similar to that previously observed in the atrium
n canine models of ventricular tachypacing-induced con-
estive heart failure (24). In contrast, whether atrial
achypacing and congestive heart failure alter TIMP4 ex-
ression remains controversial (23,25). Tranilast prevented
n increase in TIMP1 together with atrial fibrosis, suggest-
ng a role of altered TIMP1 expression in regulating atrial
brosis in our model.
ole of Rac1 GTPase in pathogenesis of AF. Both Rac1
nd RhoA are Rho-family GTPases (26). Rac1 activates
icotinamide adenine dinucleotide phosphate (NADPH)
xidases. The subsequent generation of reactive oxide spe-
ies leads to multiple cardiovascular effects, including car-
iac hypertrophy and fibrosis (27,28). An association be-
ween Rac1 and AF has been suggested (28,29). Rac1 is also
downstream mediator of angiotensin II (29), which
ctivates connective tissue growth factor via activation of
ac1 and NADPH oxidase (29). Tranilast might inhibit
trial structural remodeling by preventing TGF-1 overex-
ression and subsequent Rac1 and NADPH oxidase acti-
ation in the present study.
RhoA plays a role in cell transformation and proliferation
n a variety of cell types (30), and its cardiac-specific
verexpression results in cardiac fibrosis and atrial enlarge-
ent (31). However, RhoA expression was not influenced
y atrial tachypacing or tranilast in the present study. RhoA
ay not be included in the main cascade of the signal
ransduction of TGF-1 for generating atrial fibrosis in our
odel (29).
otential mechanisms underlying the effects of tranilast
n atrial electrical remodeling. In the present study,
ranilast also partially suppressed atrial electrical remodel-
ng, such as AERP shortening and Cav1.2 down-regulation.
ransforming growth factor-1 has reduced Cav1.2 mRNA
expression and L-type calcium current in atrial myocytes
(32). Tranilast may prevent atrial tachypacing-induced
down-regulation of Cav1.2 mRNA through the prevention
of TGF-1 overexpression. In addition, oxidative stress
contributes to atrial electrical remodeling (33). Increased
reactive oxide species has reduced L-type calcium current in
atrial myocytes (34). Accordingly, tranilast may prevent the
reduction of L-type calcium current through Rac1 suppres-
sion and subsequent reduction of NADPH oxidase and
reactive oxide species in the present study.
Potential significance. The present study is, to our knowl-
edge, the first to demonstrate the anti–atrial remodeling
effect and anti-AF effects of tranilast. It also suggests that
the inhibition of TGF-1 may contribute not only to the
prevention of atrial structural remodeling but also to the
prevention of atrial electrical remodeling in a canine AF
model.Study limitations. First, because tranilast has multiple
effects other than TGF-1 inhibition, including antiallergic
and anti-inflammatory effects (9,11,35), the possibility that
signaling pathways other than TGF-1 inhibition are
involved in the anti-atrial remodeling effects of tranilast
cannot be excluded, though the anti-inflammatory effects of
tranilast were not evident in the present study. Second, the
model used in this study was a canine atrial tachypacing
model with preserved atrioventricular conduction, which
develops concomitant tachycardia-induced ventricular dys-
function. It is not known if tranilast would have similar
efficacy in atrial tachycardia models without ventricular
dysfunction. Third, as in any animal experimental study, our
findings should be extrapolated to humans very cautiously.
In particular, it should be noted that the dose of tranilast
(50 mg/kg/day) was determined on the basis of a previous
canine in vivo study (36), and was much higher than the
clinical dose for humans. Thus, the clinical application of
tranilast for treatment of AF requires further cautious
consideration.
Conclusions
Tranilast prevents atrial remodeling and AF development in
a canine model induced by atrial tachypacing under pre-
served atrioventricular conduction by suppressing the over-
expression of TGF-1 and Rac1 proteins.
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